Alzheimers Disease

Neurology
9
Pipeline Programs
5
Companies
5
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
5
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Peptide
150%
+ 5 programs with unclassified modality

On Market (3)

Approved therapies currently available

Novo Nordisk
OZEMPICApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2017
Novo Nordisk
RYBELSUSApproved
semaglutide
Novo Nordisk
oral2020
Novo Nordisk
WEGOVYApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]oral2025

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
1
SemaglutidePhase 3Peptide1 trial
Active Trials
NCT05891496Completed23Est. Sep 2025
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
2
CAD106 ImmunotherapyPhase 2/31 trial
CNP520 50mgPhase 2/31 trial
Active Trials
NCT02565511Terminated480Est. Apr 2020
NCT03131453Terminated1,145Est. Mar 2020
E
EisaiChina - Liaoning
2 programs
2
E2814Phase 2/31 trial
GantenerumabPhase 2/3Monoclonal Antibody
Active Trials
NCT05269394Active Not Recruiting197Est. Jul 2028
Novartis
NovartisBASEL, Switzerland
1 program
1
CAD106 ImmunotherapyPhase 2/3
C2N Diagnostics
C2N DiagnosticsMO - St. Louis
1 program
PrecivityAD2 - Early TestingN/A1 trial
Active Trials
NCT06856681Withdrawn0Est. Mar 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Novo NordiskSemaglutide
EisaiE2814
AmgenCNP520 50mg
AmgenCAD106 Immunotherapy
C2N DiagnosticsPrecivityAD2 - Early Testing

Clinical Trials (5)

Total enrollment: 1,845 patients across 5 trials

NCT05891496Novo NordiskSemaglutide

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

Start: Jun 2023Est. completion: Sep 202523 patients
Phase 3Completed
NCT05269394EisaiE2814

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Start: Dec 2021Est. completion: Jul 2028197 patients
Phase 2/3Active Not Recruiting
NCT03131453AmgenCNP520 50mg

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Start: Aug 2017Est. completion: Mar 20201,145 patients
Phase 2/3Terminated
NCT02565511AmgenCAD106 Immunotherapy

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Start: Nov 2015Est. completion: Apr 2020480 patients
Phase 2/3Terminated
NCT06856681C2N DiagnosticsPrecivityAD2 - Early Testing

Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease

Start: Jul 2025Est. completion: Mar 20280
N/AWithdrawn

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)